Findings

What do systematic reviews say?

4 questions · 4 findings · 1 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 1 · 25%Low 0 · 0%Moderate 2 · 50%High 1 · 25%

Docetaxel vs non‐docetaxel‐containing regimens

Overall survival · people with advanced gastric cancer

Docetaxel leads to lower overall survival compared with non‐docetaxel‐containing regimens (high certainty).

1 finding from 1 review

Chemotherapy for advanced gastric cancer 2017 · Cochrane Headline outcomes only
HR 0.86 [0.78, 0.95]
8 studies · 2001 participants
High

Docetaxel vs non‐docetaxel‐containing regimens

Overall survival ‐ Other comparisons · people with advanced gastric cancer

It is very uncertain whether docetaxel changes overall survival ‐ Other comparisons compared with non‐docetaxel‐containing regimens (very low certainty).

1 finding from 1 review

Chemotherapy for advanced gastric cancer 2017 · Cochrane Headline outcomes only
HR 0.8 [0.46, 1.39]
1 study · 56 participants
Very low

Docetaxel vs non‐docetaxel‐containing regimens

Overall survival ‐ Additive comparisons · people with advanced gastric cancer

Docetaxel probably leads to lower overall survival ‐ Additive comparisons compared with non‐docetaxel‐containing regimens (moderate certainty).

1 finding from 1 review

Chemotherapy for advanced gastric cancer 2017 · Cochrane Headline outcomes only
HR 0.8 [0.71, 0.91]
4 studies · 1466 participants
Moderate

Docetaxel vs non‐docetaxel‐containing regimens

Overall survival ‐ Substitutive comparisons · people with advanced gastric cancer

Docetaxel showed no clear difference in overall survival ‐ Substitutive comparisons compared with non‐docetaxel‐containing regimens (moderate certainty).

1 finding from 1 review

Chemotherapy for advanced gastric cancer 2017 · Cochrane Headline outcomes only
HR 1.05 [0.87, 1.27]
3 studies · 479 participants
Moderate